Challenges in Managing Pericardial Disease Related to Post Viral Syndrome After COVID-19 Infection

Area of Science:

• Cardiology
• Infectious Diseases
• Pulmonology

Background:

• Coronavirus disease 2019 (COVID-19) is primarily a respiratory illness but has known cardiac manifestations.
• Cardiac involvement includes myocardial ischemia, arrhythmia, myocarditis, pericarditis, and pericardial effusion.
• Most reported pericardial disease cases occurred during acute COVID-19 infection.

Observation:

• This case report details a patient who developed pericarditis leading to cardiac tamponade following the resolution of acute COVID-19 infection.
• The patient exhibited a poor response to initial medical therapy, including non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine.
• Steroid exposure may have contributed to the suboptimal response to standard treatments.

Findings:

• Pericardial effusion, a serious cardiac complication, was diagnosed after the acute phase of COVID-19.
• While a definitive causal link is difficult to establish, the presentation is highly suspicious for post-viral sequelae of COVID-19.
• This suggests pericardial disease can be a late complication of COVID-19.

Implications:

• Healthcare providers should consider pericardial disease as a potential late complication of COVID-19, even after apparent recovery from the acute illness.
• Awareness of potential therapeutic challenges in managing these late-onset complications is crucial.
• Further research may be needed to understand the mechanisms and optimal management of post-COVID-19 pericardial disease.